Clinical Trial Update: Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update evaluating optimal duration of pre-operative letrozole and correlation of clinical efficacy with surrogate markers in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: COMPLETED